NEW YORK, NY / ACCESSWIRE / Mar 5, 2014 / Recent medical studies have linked low-T testosterone therapy products like AndroGel and Axiron to serious cardiovascular health problems such as heart attack, stroke, and even death. On Jan. 31, 2014, the Food and Drug Administration (FDA) issued a safety announcement stating that it is investigating the health and safety risk of low testosterone products. In response to the FDA's announcement and communications to our office by individuals injured by low-T drugs, The Cochran Firm, D.C. today announces it is actively investigating injuries related to low testosterone products like AndroGel, Axiron, Fortesta, and Testim and is accepting cases from individuals who suffered health problems while taking low-T drugs.
"Recent revelations about low-T testosterone products in the Journal of the American Medical Association and the PLOS One journal indicate that there are potentially serious health risks with these products that were not disclosed to the public," David Haynes, managing attorney of The Cochran Firm, D.C., said. "We are actively and aggressively investigating legal claims related to low-T testosterone therapy including popular products like AndroGel, Axiron, Fortesta, and Testim."
Individuals who suffered cardiovascular health problems like heart attacks and strokes have filed federal lawsuits against AbbVie Inc. and Abbot Laboratories, the makers and distributors of AngroGel. The testosterone therapy lawsuits allege that AndroGel was misrepresented as a safe and effective treatment for hypogonadism or "low testosterone." The case names and numbers for these low-T testosterone lawsuits are Marino v. AbbVie Inc., 14-cv-00777; Gallagher v. AbbVie Inc., 14-cv-00776; and Myers v. AbbVie Inc., 14- cv-00780; Aurecchia v. AbbVie Inc., 14-cv-00772; and Benn v. AbbVie, 14-cv-00774 U.S. District Court, Northern District of Illinois.
Recent medical studies indicated that there may be serious health risks with low-T testosterone replacement therapy products. A 2010 New England Journal of Medicine study into low-T products was halted due to a higher incidence of negative cardiovascular events. A 2013 study in the Journal of the American Medical Association suggests that testosterone replacement therapy increased the risk of heart attack, stroke, and death by approximately 30%. A 2014 medical study in PLOS ONE (the Public Library of Science's open access peer-reviewed scientific journal) indicates that testosterone replacement therapy products doubled the risk of heart attack in men older than 65 years old and men younger than 65 with a prior heart condition.
In reaction to the troubling findings by these medical studies, the Food and Drug Administration (FDA) issued a safety announcement on Jan. 31, 2014, about low-T testosterone gel, cream, roll-on, and other topical products. The FDA recommended that patients should not stop taking prescribed testosterone products without first discussing the low-T testosterone product with their doctor.
About The Cochran Firm, D.C.
With decades of collective legal experience, the team of seasoned attorneys at The Cochran Firm represents victims of catastrophic personal injury, mass tort, class action, low testosterone products, and product liability in the Baltimore, Maryland and Washington, D.C. metropolitan regions and nationwide. The qualified legal professionals with The Cochran Firm bring experienced, high-caliber legal expertise to ordinary citizens who have been injured by others' careless actions. Attorneys with The Cochran Firm were selected as 2013 and 2014 Super Lawyers and have received top ratings from their peers, local and national publications and organizations, and clients for achieving successful verdicts and settlements for injury victims.
All initial consultations with The Cochran Firm, D.C.'s low testosterone attorneys are free, confidential, and carry no obligation.
[email protected] 1100 New York Ave. NW Suite 340, West Tower Washington, D.C. 20005 Phone : (202) 682-5800
Video Link: https://www.youtube.com/watch?v=rviPp8UAUjc